Hidradenitis Suppurativa (HS) is a chronic illness characterized by swollen, painful lesions, occurring in the armpit (axillae), groin, anal, and breast regions. This disease occurs due to blockage of hair follicles and secondary infection and sometimes inflammation of certain sweat glands (apocrine glands).
Hidradenitis Suppurativa Epidemiology
Hidradenitis Suppurativa Market
Hidradenitis Suppurativa Market Drivers
Hidradenitis Suppurativa Market Barriers
Scope of the Report
Hidradenitis Suppurativa Emerging Therapies
(Drug: companies logos)
Hidradenitis Suppurativa Marketed Drugs
Request for sample pages
Table of contents
1. Executive Summary: Hidradenitis Suppurativa (HS)
2. SWOT Analysis: Hidradenitis Suppurativa (HS)
3. Hidradenitis Suppurativa (HS) Patient Share (%) Overview at a Glance
3.1. Patient Share (%) Distribution of Hidradenitis Suppurativa in 2017 and 2030
4. Hidradenitis Suppurativa Market Overview at a Glance
4.1. Market Share (%) Distribution of Hidradenitis Suppurativa in 2017
4.2. Market Share (%) Distribution of Hidradenitis Suppurativa in 2030
5. Disease Overview: Hidradenitis Suppurativa (HS)
5.1. Introduction
5.2. Causes and Symptoms of Hidradenitis Suppurativa (HS)
5.3. Classification and Severity Assessment of Hidradenitis Suppurativa (HS)
5.3.1. Hurley Stages of HS
5.3.2. Modified Sartorius Score (MSS) of HS
5.3.3. Physician Global Assessment of Hidradenitis Suppurativa (HS-PGA)
5.3.4. Specific Severity Index of Hidradenitis Suppurativa (HSSI)
5.3.5. Pathophysiology of Hidradenitis Suppurativa
5.3.6. Genetic Basis of Hidradenitis Suppurativa (HS)
5.4. Diagnosis of Hidradenitis Suppurativa (HS)
5.4.1. Differential Diagnoses
5.4.2. Biomarkers of Hidradenitis Suppurativa (HS)
5.4.3. Risk Factors and Complications
5.4.4. Comorbidities
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Assumptions and Rationale: 7MM
6.3. Total Prevalent Patient Population of HS in the 7MM
6.4. Total Diagnosed Prevalent Patient Population of HS in the 7MM
6.5. Gender-Specific Prevalent Patient Population of HS in the 7MM
6.6. Age-Specific Prevalent Patient Population of HS in the 7MM
6.7. Stage-Specific (Severity-specific) prevalent cases of HS in the 7MM
6.8. Treated Prevalent Cases of HS in the 7MM
7. Country-wise Epidemiology of HS in the 7MM
7.1. United States
7.1.1. Total Diagnosed Prevalent cases of HS in the United States
7.1.2. Gender-Specific Prevalent cases of HS in the United States
7.1.3. Age-Specific Prevalent cases of HS in the United States
7.1.4. Stage-Specific Prevalent Cases of HS in the United States
7.1.5. Treated Prevalent Cases of HS in the United States
7.2. EU5
7.2.1. Germany
7.2.1.1. Total Diagnosed Prevalent cases of HS in Germany
7.2.1.2. Gender-Specific Prevalent cases of HS in Germany
7.2.1.3. Age-Specific Prevalent cases of HS in Germany
7.2.1.4. Stage-Specific Prevalent Cases of HS in Germany
7.2.1.5. Treated Prevalent Cases of HS in Germany
7.2.2. France
7.2.2.1. Total Diagnosed Prevalent cases of HS in France
7.2.2.2. Gender-Specific Prevalent cases of HS in France
7.2.2.3. Age-Specific Prevalent cases of HS in France
7.2.2.4. Stage-Specific Prevalent Cases of HS in France
7.2.2.5. Treated Prevalent Cases of HS in France
7.2.3. Italy
7.2.3.1. Total Diagnosed Prevalent cases of HS in Italy
7.2.3.2. Gender-Specific Prevalent cases of HS in Italy
7.2.3.3. Age-Specific Prevalent cases of HS in Italy
7.2.3.4. Stage-Specific Prevalent Cases of HS in Italy
7.2.3.5. Treated Prevalent Cases of HS in Italy
7.2.4. Spain
7.2.4.1. Total Diagnosed Prevalent cases of HS in Spain
7.2.4.2. Gender-Specific Prevalent cases of HS in Spain
7.2.4.3. Age-Specific Prevalent cases of HS in Spain
7.2.4.4. Stage-Specific Prevalent Cases of HS in Spain
7.2.4.5. Treated Prevalent Cases of HS in Spain
7.2.5. United Kingdom
7.2.5.1. Total Diagnosed Prevalent cases of HS in the United Kingdom
7.2.5.2. Gender-Specific Prevalent cases of HS in the United Kingdom
7.2.5.3. Age-Specific Prevalent cases of HS in the United Kingdom
7.2.5.4. Stage-Specific Prevalent Cases of HS in the United Kingdom
7.2.5.5. Treated Prevalent Cases of HS in the United Kingdom
7.3. Japan
7.3.1. Total Diagnosed Prevalent cases of HS in Japan
7.3.2. Gender-Specific Prevalent cases of HS in Japan
7.3.3. Age-Specific Prevalent cases of HS in Japan
7.3.4. Stage-Specific Prevalent Cases of HS in Japan
7.3.5. Treated Prevalent Cases of HS in Japan
8. Current Treatment Practices
8.1. European S1 Guideline for the Treatment of Hidradenitis Suppurativa/Acne Inversa
8.1.1. Medical therapy
8.1.2. Surgical therapy
8.2. North American Clinical Management Guidelines for HS
8.3. British Association of Dermatologists guidelines for the management of Hidradenitis Suppurativa (Acne Inversa) 2018
9. Patient Journey of Hidradenitis Suppurativa (HS)
10. Unmet Needs
11. Key Endpoints in Hidradenitis Suppurativa (HS) Clinical Trials
12. Marketed Drugs
12.1. Humira: AbbVie
12.1.1. Product Description
12.1.2. Regulatory milestones
12.1.3. Other developmental Activities
12.1.4. Pivotal Clinical Trials
12.1.5. Summary of Pivotal Clinical Trials
13. Emerging Therapies
13.1. Key Cross of Emerging Therapies
13.2. IFX-1: InflaRx
13.2.1. Product Description
13.2.2. Other developmental Activities
13.2.3. Clinical Development
13.2.4. Clinical Trials Information
13.2.5. Safety and Efficacy
13.3. Cosentyx (Secukinumab): Novartis Pharmaceuticals
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Clinical Trials Information
13.3.5. Safety and Efficacy
13.4. INCB054707: Incyte Corporation
13.4.1. Product Description
13.4.2. Clinical Development
13.4.3. Clinical Trials Information
13.5. CJM112: Novartis Pharmaceuticals
13.5.1. Product Description
13.5.2. Other developmental Activities
13.5.3. Clinical Development
13.5.4. Clinical Trials Information
13.5.5. Safety and Efficacy
13.6. Bimekizumab: UCB Biopharma S.P.R.L.
13.6.1. Product Description
13.6.2. Other developmental Activities
13.6.3. Clinical Development
13.6.4. Clinical Trials Information
13.7. Bermekimab (MABp1): Janssen Pharmaceutical
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.4. Clinical Trials Information
13.7.5. Safety and Efficacy
13.8. CFZ533 (Iscalimab) and LYS006: Novartis
13.8.1. Product Description
13.8.2. Other Developmental Activities
13.8.3. Clinical Development
13.8.4. Clinical Trials Information
13.9. Apremilast: Celgene
13.9.1. Product Description
13.9.2. Clinical Development
13.9.3. Clinical Trials Information
13.9.4. Safety and Efficacy
13.10. Avacopan: ChemoCentryx
13.10.1. Product Description
13.10.2. Other Developmental Activities
13.10.3. Clinical Development
13.10.4. Clinical Trials Information
13.11. PF-06650833, PF-06700841, and PF-06826647: Pfizer
13.11.1. Product Description
13.11.2. Clinical Development
13.11.3. Clinical Trials Information
13.12. Risankizumab: AbbVie
13.12.1. Product Description
13.12.2. Clinical Development
13.12.3. Clinical Trials Information
13.13. Guselkumab: Janssen Pharmaceutical
13.13.1. Product Description
13.13.2. Other Developmental Activities
13.13.3. Clinical Development
13.13.4. Clinical Trials Information
14. Attribute Analysis of Hidradenitis Suppurativa (HS) Therapies
15. Hidradenitis Suppurativa (HS): 7 Major Market Analysis
15.1. Key Findings
15.2. Market Size of Hidradenitis Suppurativa in 7MM
15.3. Market Size by therapies of Hidradenitis Suppurativa in 7MM
16. Market Outlook: 7MM
16.1. United States Market Size
16.1.1. Total Market size of Hidradenitis Suppurativa
16.1.2. Hidradenitis Suppurativa Market by Therapies
17. EU-5 Countries
17.1. Germany Market Size
17.1.1. Total Market size of Hidradenitis Suppurativa
17.1.2. Hidradenitis Suppurativa Market by Therapies
17.2. France Market Size
17.2.1. Total Market size of Hidradenitis Suppurativa
17.2.2. Hidradenitis Suppurativa Market by Therapies
17.3. Italy Market Size
17.3.1. Total Market size of Hidradenitis Suppurativa
17.3.2. Hidradenitis Suppurativa Market by Therapies
17.4. Spain Market Size
17.4.1. Total Market size of Hidradenitis Suppurativa
17.4.2. Hidradenitis Suppurativa Market by Therapies
17.5. United Kingdom Market Size
17.5.1. Total Market size of Hidradenitis Suppurativa
17.5.2. Hidradenitis Suppurativa Market by Therapies
18. Japan
18.1. Total Market size of Hidradenitis Suppurativa
18.2. Hidradenitis Suppurativa Market by Therapies
19. Market Access and Reimbursement Scenario of Hidradenitis Suppurativa (HS) Therapies
20. Market Drivers
21. Market Barriers
22. Appendix
22.1. Bibliography
22.2. Report Methodology
23. Disclaimer
24. DelveInsight Capabilities
25. About DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/